Biomarkers and clinical outcomes after tezepelumab cessation-Reference-Cited by-同舟云学术

Biomarkers and clinical outcomes after tezepelumab cessation

Published:2024-09 Issue:3 Volume:133 Page:310-317.e4
ISSN:1081-1206
Container-title:Annals of Allergy, Asthma & Immunology
language:en
Short-container-title:Annals of Allergy, Asthma & Immunology

Author:

Brightling Christopher E.,Caminati Marco,Llanos Jean-Pierre,Caveney Scott,Kotalik Ales,Griffiths Janet M.,Lundahl Anna,Israel Elliot,Pavord Ian D.,Wechsler Michael E.,Porsbjerg Celeste,Corren Jonathan,Gołąbek Monika,Martin Neil,Ponnarambil Sandhia

Funder

Amgen

AstraZeneca plc

Publisher

Elsevier BV

Reference29 articles.

1. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention 2024. Accessed May 13, 2024. Available at: https://ginasthma.org/wp-content/uploads/2024/05/GINA-2024-Main-Report-WMS-1.pdf.

2. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019;Lancet,2020

3. Asthma patients who stop asthma biologics have a similar risk of asthma exacerbations as those who continue asthma biologics;Jeffery;J Allergy Clin Immunol Pract,2021

4. Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial;Hanania;Ann Intern Med,2011

5. Mepolizumab treatment in patients with severe eosinophilic asthma;Ortega;N Engl J Med,2014

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. To stop or not to stop an asthma biologic, that is the question;Annals of Allergy, Asthma & Immunology;2024-09